Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 8/2022

21-06-2022 | Insulins | Psychosocial Aspects (J Pierce, Section Editor)

Psychosocial Needs for Newly Diagnosed Youth with Type 1 Diabetes and Their Families

Authors: Susana R. Patton, David Maahs, Priya Prahalad, Mark A. Clements

Published in: Current Diabetes Reports | Issue 8/2022

Login to get access

Abstract

Purpose of Review

To synthesize findings from studies published within the last 5 to 10 years and recruiting families of children with new-onset type 1 diabetes (T1D).

Recent Findings

Children can establish glycated hemoglobin (HbA1c) trajectories in the new-onset period that may persist for up to a decade. Demographic factors, family conflict, and diabetic ketoacidosis at the time of diagnosis may be risk factors for sub-optimal child HbA1c, while new immune modulating therapies and a treatment approach that combines advanced technologies and remote patient monitoring may improve child HbA1c. Nonetheless, recent trials in the new-onset period have largely overlooked how treatments may impact families’ psychosocial functioning and longitudinal observational studies have been limited.

Summary

The new-onset period of T1D is an important time for research and clinical intervention, though gaps exist specific to families’ psychosocial needs. Filling these gaps is essential to inform clinical management and standard of care guidelines and improve outcomes.
Literature
1.
2.
Saydah SH, Imperatore G, Henkin L, D’Agostino R Jr, Divers J, Mayer-Davis EJ, et al. Trends and characteristics of self-reported case presentation of diabetes diagnosis among youth from 2002 to 2010: findings from the SEARCH for diabetes in youth study. Diabetes Care. 2015;38(6):e84–5.PubMedPubMedCentralCrossRef
3.
4.
Patterson CC, Karuranga S, Salpea P, Saeedi P, Dahlquist G, Soltesz G, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107842.
5.
Barrett CE, Koyama AK, Alvarez P, Chow W, Lundeen EA, Perrine CG, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 tears - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):59–65.PubMedPubMedCentralCrossRef
6.
Unsworth R, Wallace S, Oliver NS, Yeung S, Kshirsagar A, Naidu H, et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care. 2020;43(11):e170-e1.
7.
Vlad A, Serban V, Timar R, Sima A, Botea V, Albai O, et al. Increased incidence of type 1 diabetes during the COVID-19 pandemic in Romanian children. Medicina (Kaunas). 2021;57(9):973.PubMedPubMedCentralCrossRef
8.
Mortensen HB, Hougaard P, Swift P, Hansen L, Holl RW, Hoey H, et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009;32(8):1384–90.PubMedPubMedCentralCrossRef
9.
Committee of the American Diabetes Association Professional Practice. 14. Children and adolescents: standards of medical care in diabetes- 2022. Diabetes Care. 2022;45:S208-S31.
10.
Whittemore R, Jaser S, Chao A, Jang M, Grey M. Psychological experience of parents of children with type 1 diabetes: a systematic mixed-studies review. Diabetes Educ. 2012;38(4):562–79.PubMedPubMedCentralCrossRef
11.
DiMeglio LA, Acerini CL, Codner E, Craig ME, Hofer SE, Pillay K, et al. ISPAD Clinical Practice Consensus Guidelines 2018: glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(Suppl 27):105–14.PubMedCrossRef
12.
Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33(5):1090–6.PubMedPubMedCentralCrossRef
13.
Diabetes Control, Complications Trial /Epidemiology of Diabetes I, Complications Research G, Lachin JM, White NH, Hainsworth DP, et al. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64(2):631–42.
14.
Cengiz E, Cheng P, Ruedy KJ, Kollman C, Tamborlane WV, Klingensmith GJ, et al. Clinical outcomes in youth beyond the first year of type 1 diabetes: results of the Pediatric Diabetes Consortium (PDC) type 1 diabetes new onset (NeOn) study. Pediatr Diabetes. 2017;18(7):566–73.PubMedCrossRef
15.
Cengiz E, Connor CG, Ruedy KJ, Beck RW, Kollman C, Klingensmith GJ, et al. Pediatric diabetes consortium T1D New Onset (NeOn) study: clinical outcomes during the first year following diagnosis. Pediatr Diabetes. 2014;15(4):287–93.PubMedCrossRef
16.••
Sherr JL, Schwandt A, Phelan H, Clements MA, Holl RW, Benitez-Aguirre PZ, et al. Hemoglobin A1c patterns of youth with type 1 diabetes 10 years post diagnosis from 3 continents. Pediatrics. 2021;148(2):e2020048942. https://​doi.​org/​10.​1542/​peds.​2020-048942. Identifies similar HbA1c trajectories in youth with type 1 diabetes from multiple international registries and how trajectories in the new-onset period may relate to future trajectories.
17.
Schwandt A, Hermann JM, Rosenbauer J, Boettcher C, Dunstheimer D, Grulich-Henn J, et al. Longitudinal trajectories of metabolic control from childhood to young adulthood in type 1 diabetes from a large German/Austrian registry: a group-based modeling approach. Diabetes Care. 2017;40(3):309–16.PubMedCrossRef
18.
Prahalad P, Yang J, Scheinker D, Desai M, Hood K, Maahs DM. Hemoglobin A1c trajectory in pediatric patients with newly diagnosed type 1 diabetes. Diabetes Technol Ther. 2019;21(8):456–61.PubMedPubMedCentralCrossRef
19.•
Patton SR, Feldman K, Majidi S, Noser A, Clements MA. Identifying HbA1c trajectories and modifiable risk factors of trajectories in 5- to 9-year-olds with recent-onset type 1 diabetes from the United States. Diabet Med. 2021;38(9):e14637. Provides preliminary evidence of psychosocial factors that may predict child HbA1c trajectories in youth with new-onset type ! diabetes.
20.
Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015;38(3):476–81.PubMedCrossRef
21.
Rickels MR, Evans-Molina C, Bahnson HT, Ylescupidez A, Nadeau KJ, Hao W, et al. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. J Clin Invest. 2020;130(4):1850–62.PubMedPubMedCentralCrossRef
22.
Gubitosi-Klug RA, Braffett BH, Hitt S, Arends V, Uschner D, Jones K, et al. Residual beta cell function in long-term type 1 diabetes associates with reduced incidence of hypoglycemia. J Clin Invest. 2021;131(3):e143011. https://​doi.​org/​10.​1172/​JCI143011.
23.
Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study G, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA. 2017;318(19):1891–902.
24.
Herold KC, Gitelman SE, Ehlers MR, Gottlieb PA, Greenbaum CJ, Hagopian W, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766–74.PubMedPubMedCentralCrossRef
25.
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, et al. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2019;62(4):655–64.PubMedCrossRef
26.•
Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, et al. Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: two-year clinical trial data. Diabetes. 2019;68(6):1267–76. This is a clinical trial of a promising immune modulating therapy for children with new-onset type 1 diabetes to prolong partial remission.
27.
Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, et al. Low-dose anti-thymocyte globulin (ATG) preserves beta-cell function and improves HbA1c in new-onset type 1 diabetes. Diabetes Care. 2018;41(9):1917–25.PubMedPubMedCentralCrossRef
28.•
Jamiolkowska-Sztabkowska M, Glowinska-Olszewska B, Luczynski W, Konstantynowicz J, Bossowski A. Regular physical activity as a physiological factor contributing to extend partial remission time in children with new onset diabetes mellitus-Two years observation. Pediatr Diabetes. 2020;21(5):800–7. This is a clinical trial of a promising behavioral treatment for children with new-onset type 1 diabetes to prolong partial remission.
29.
Robertson K, Riddell MC, Guinhouya BC, Adolfsson P, Hanas R, International Society for P, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Exercise in children and adolescents with diabetes. Pediatr Diabetes. 2014;15 Suppl 20:203–23.
30.
Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: a randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabetes. 2021;22(7):1014–22.PubMedCrossRef
31.
Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, et al. Effectiveness of early intensive therapy on beta-cell preservation in type 1 diabetes. Diabetes Care. 2013;36(12):4030–5.PubMedPubMedCentralCrossRef
32.
Duca LM, Reboussin BA, Pihoker C, Imperatore G, Saydah S, Mayer-Davis E, et al. Diabetic ketoacidosis at diagnosis of type 1 diabetes and glycemic control over time: The SEARCH for diabetes in youth study. Pediatr Diabetes. 2019;20(2):172–9.PubMedCrossRef
33.
Mencher SR, Frank G, Fishbein J. Diabetic ketoacidosis at onset of type 1 diabetes: rates and risk factors today to 15 years ago. Glob Pediatr Health. 2019;6:2333794X19870394.
34.
Baldelli L, Flitter B, Pyle L, Maahs DM, Klingensmith G, Slover R, et al. A survey of youth with new onset type 1 diabetes: opportunities to reduce diabetic ketoacidosis. Pediatr Diabetes. 2017;18(7):547–52.PubMedCrossRef
35.
DiMeglio LA. COVID-19 and type 1 diabetes: addressing concerns and maintaining control. Diabetes Care. 2021;44(9):1924–8.PubMedCrossRef
36.
McGlacken-Byrne SM, Drew SEV, Turner K, Peters C, Amin R. The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: a multi-centre study of the first COVID-19 wave. Diabet Med. 2021;38(9): e14640.PubMedPubMedCentralCrossRef
37.
Duca LM, Wang B, Rewers M, Rewers A. Diabetic ketoacidosis at diagnosis of type 1 diabetes predicts poor long-term glycemic control. Diabetes Care. 2017;40(9):1249–55.PubMedCrossRef
38.
Zaharieva DP, Addala A, Prahalad P, Bishop F, Hood K, Maahs D. Youth with type 1 diabetes benefit from early continuous glucose monitoring initiation irrespective of diabetic ketoacidosis at diagnosis: 4T pilot study results. 15th International Conference on Advanced Technologies & Treatments for Diabetes April Barcelona, Spain 2022.
39.
Aye T, Mazaika PK, Mauras N, Marzelli MJ, Shen H, Hershey T, et al. Impact of early diabetic ketoacidosis on the developing brain. Diabetes Care. 2019;42(3):443–9.PubMedCrossRef
40.
Ghetti S, Kuppermann N, Rewers A, Myers SR, Schunk JE, Stoner MJ, et al. Cognitive function following diabetic ketoacidosis in children with new-onset or previously diagnosed type 1 diabetes. Diabetes Care. 2020;43(11):2768–75.PubMedPubMedCentralCrossRef
41.
Semenkovich K, Bischoff A, Doty T, Nelson S, Siller AF, Hershey T, et al. Clinical presentation and memory function in youth with type 1 diabetes. Pediatr Diabetes. 2016;17(7):492–9.PubMedCrossRef
42.
Lawson S, Redel JM, Smego A, Gulla M, Schoettker PJ, Jolly M, et al. Assessment of a day hospital management program for children with type 1 diabetes. JAMA Netw Open. 2020;3(3): e200347.PubMedPubMedCentralCrossRef
43.
Pingul MM, Mulvihill EM, Reinert SE, Gopalakrishnan G, Plante WA, Boney CM, et al. Pediatric diabetes outpatient center at Rhode Island Hospital: the impact of changing initial diabetes education from inpatient to outpatient. R I Med J (2013). 2017;100(2):21–4.
44.
Bernier A, Fedele D, Guo Y, Chavez S, Smith MD, Warnick J, et al. New-onset diabetes educator to educate children and their caregivers about diabetes at the time of diagnosis: usability study. JMIR Diabetes. 2018;3(2): e10.PubMedPubMedCentralCrossRef
45.
Patton SR, Noser AE, Youngkin EM, Majidi S, Clements MA. Early initiation of diabetes devices relates to improved glycemic control in children with recent-onset type 1 diabetes mellitus. Diabetes Technol Ther. 2019;21(7):379–84.PubMedPubMedCentralCrossRef
46.
Prahalad P, Addala A, Scheinker D, Hood KK, Maahs DM. CGM initiation soon after type 1 diabetes diagnosis results in sustained CGM use and wear time. Diabetes Care. 2020;43(1):e3–4.PubMedCrossRef
47.
Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes: 7-year follow-up study. Diabetes Care. 2022;45(3):750–3.
48.
Youngkin EM, Majidi S, Noser AE, Stanek KR, Clements MA, Patton SR. Continuous glucose monitoring decreases hypoglycemia avoidance behaviors, but not worry in parents of youth with new onset type 1 diabetes. J Diabetes Sci Technol. 2021;15(5):1093–7.PubMedCrossRef
49.
Prahalad P, Zaharieva DP, Addala A, New C, Scheinker D, Desai M, et al. Improving clinical outcomes in newly diagnosed pediatric type 1 diabetes: teamwork, targets, technology, and tight control-the 4T study. Front Endocrinol (Lausanne). 2020;11:360.CrossRef
50.••
Prahalad P, Ding VY, Zaharieva DP, Addala A, Johari R, Scheinker D, et al. Teamwork. targets, technology, and tight control in newly diagnosed type 1 diabetes: The pilot 4T study. J Clin Endo Met. 2022;107(4):998–1008. This is a clinical trial of a promising advance technologies and remote patient monitoring treatment for children with new-onset type 1 diabetes to improve HbA1c levels.
51.
Tanenbaum ML, Zaharieva DP, Addala A, Ngo J, Prahalad P, Leverenz B, et al. “I was ready for it at the beginning”: parent experiences with early introduction of continuous glucose monitoring following their child’s Type 1 diabetes diagnosis. Diabet Med. 2021;38(8): e14567.PubMedPubMedCentralCrossRef
52.
McGill DE, Volkening LK, Pober DM, Muir AB, Young-Hyman DL, Laffel LM. Depressive symptoms at critical times in youth with type 1 diabetes: following type 1 diabetes diagnosis and insulin pump initiation. J Adolesc Health. 2018;62(2):219–25.PubMedCrossRef
53.
Cuijpers P, Pineda BS, Ng MY, Weisz JR, Munoz RF, Gentili C, et al. A meta-analytic review: psychological treatment of subthreshold depression in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2021;60(9):1072–84.PubMedCrossRef
54.
Lawrence JM, Imperatore G, Dabelea D, Mayer-Davis EJ, Linder B, Saydah S, et al. Trends in incidence of type 1 diabetes among non-Hispanic white youth in the U.S., 2002–2009. Diabetes. 2014;63(11):3938–45.
55.
Noser AE, Dai H, Marker AM, Raymond JK, Majidi S, Clements MA, et al. Parental depression and diabetes-specific distress after the onset of type 1 diabetes in children. Health Psychol. 2019;38(2):103–12.PubMedCrossRef
56.
McConville A, Noser AE, Nelson EL, Clements MA, Majidi S, Patton SR. Depression as a predictor of hypoglycemia worry in parents of youth with recent-onset type 1 diabetes. Pediatr Diabetes. 2020;21(5):909–16.PubMedPubMedCentralCrossRef
57.
Majidi S, Noser A, Youngkin EM, Clements M, Patton SR. Long-term associations between parental depression and diabetes distress in the two-years following child-onset type 1 diabetes. 45th Annual International Society of Pediatric and Adolescent Diabetes; Boston, MA2019.
58.
Stanek KR, Noser AE, Patton SR, Clements MA, Youngkin EM, Majidi S. Stressful life events, parental psychosocial factors, and glycemic management in school-aged children during the 1 year follow-up of new-onset type 1 diabetes. Pediatr Diabetes. 2020;21(4):673–80.PubMedPubMedCentralCrossRef
59.
Marker AM, Monzon AD, Goggin K, Clements MA, Patton SR. Parent perspectives on educational and psychosocial intervention for recent-onset type 1 diabetes in their school-age child: a qualitative study. Diabetes Spectr. 2021;34(2):166–74.PubMedPubMedCentralCrossRef
60.
Nirantharakumar K, Mohammed N, Toulis KA, Thomas GN, Narendran P. Clinically meaningful and lasting HbA1c improvement rarely occurs after 5 years of type 1 diabetes: an argument for early, targeted and aggressive intervention following diagnosis. Diabetologia. 2018;61(5):1064–70.PubMedPubMedCentralCrossRef
61.
Triolo TM, Maahs DM, Pyle L, Slover R, Buckingham B, Cheng P, et al. Effects of frequency of sensor-augmented pump use on HbA1c and C-peptide levels in the first year of type 1 diabetes. Diabetes Care. 2016;39(4):e61–2.PubMedPubMedCentralCrossRef
Metadata
Title
Psychosocial Needs for Newly Diagnosed Youth with Type 1 Diabetes and Their Families
Authors
Susana R. Patton
David Maahs
Priya Prahalad
Mark A. Clements
Publication date
21-06-2022
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 8/2022
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-022-01479-8

Other articles of this Issue 8/2022

Current Diabetes Reports 8/2022 Go to the issue

Diabetes Epidemiology (H-C Yeh, Section Editor)

Evaluating Natural Experiments that Impact the Diabetes Epidemic: an Introduction to the NEXT-D3 Network

Pathogenesis of Type 2 Diabetes and Insulin Resistance (M-E Patti, Section Editor)

Gut Factors Mediating the Physiological Impact of Bariatric Surgery

Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)

Machine Learning Models for Inpatient Glucose Prediction

Obesity (K Gadde and P Singh, Section Editors)

Shift Work and Obesity Risk—Are There Sex Differences?

Diabetes and Pregnancy (M-F Hivert and CE Powe, Section Editor)

Telehealth for the Management of Diabetes in Pregnancy

Obesity (K Gadde and P Singh, Section Editors)

Metabolic Syndrome and Vascular-Associated Cognitive Impairment: a Focus on Preclinical Investigations
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits